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ABSTRACT 
Introduction: Vitiligo is a skin pigmentation disorder and has an estimated global prevalence 
of around one to two percent. Vitiligo can significantly affect patients’ Quality of life (QoL).  
It is cosmetically and psychologically devastating, and can affect anyone irrespective of race, 
skin type or ethnicity. There is a paucity of research evaluating the QoL amongst vitiligo 
patients in Africa and Sub-Saharan Africa in particular. The objectives of this study were to 
demonstrate how vitiligo has altered the QoL of vitiligo patients treated at the skin 
outpatients’ clinics in Johannesburg, South Africa. 
Methods:  Our research was a prospective cross-sectional study of all individuals who were 
diagnosed with vitiligo at the three dermatology outpatients’ clinics in three academic public 
hospitals, and the phototherapy daycare centre in Johannesburg. All patients fulfilling the 
inclusion criteria were requested to take part in the study. Data was obtained from enrolled 
individuals using a data collection sheet and the Dermatology Life Quality index 
questionnaire. This information was analysed using statistical software (STATA version 12).  
Results: A total of ninety-five (n=95) respondents were included as per inclusion criteria in 
our study. Our cohort comprised of sixty-two females (n=62, 65.26%), thirty-three males 
(n=33, 34. 74%).  DLQI scores were in the ranges of 0 to 28 and the mean was 10.06±6.52, 
which indicates a moderate Quality of life (QoL) impairment in our cohort. 
Conclusion: Our study has shown that vitiligo moderately affects the QOL life of adult South 
African vitiligo patients. Therefore, treatment measures should be directed towards medical 
and psychological aspects of our patients for better treatment outcomes and improved QoL. 
This would be an argument for establishment of psychodermatology clinics at our referral 
hospitals. 
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PREFACE 
Vitiligo was ranked the fourteenth most common Dermatological condition in 2003 in a study 
conducted in the five public academic hospitals in Johannesburg. (1) Various studies have 
shown that several skin diseases, along with vitiligo, affect the QoL of patients. (2-10) To our 
knowledge, no other study has been done in South Africa to evaluate the QoL of individuals 
with vitiligo. Our research is a prospective cross-sectional study to assess the QoL of all 
patients meeting the inclusion criteria seen from October 2012 to January 2013 at three 
dermatology outpatient clinics in three respective academic public hospitals in Johannesburg. 
Patients attending the phototherapy daycare centre at CMJAH for phototherapy treatment of 
vitiligo were also requested to be included among our respondents. 
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CHAPTER 1 
1.0 INTRODUCTION 
 
Vitiligo is a pigmentation disease with a global prevalence estimated to be around 1–2 
percent. (11) It presents with well-demarcated areas of pigment loss, usually symmetrical, 
due to loss of pigment cells. Melanocytes that normally produce skin pigment called melanin, 
which characterise skin colour, are lost from the affected skin. The mechanism(s) that cause 
their loss are not known to date. Vitiligo may appear at any time from very young age to 
senescence. (12) It may be localised, generalised and universal (loss of skin colour covering 
almost or the whole body surface). A completely amelanotic macule (or patch), surrounded 
by apparently normal skin is the type of vitiligo seen most frequently. It commonly appears 
uniformly milk or chalk-white. (11, 12)  Its natural course is unpredictable, and there is 
currently no known definite universal cure. (13) 
 
Epidemiology of Vitiligo 
Approximately 50 million people worldwide are affected by vitiligo. Globally, 
epidemiological studies have been done regarding vitiligo but there is limited 
epidemiological data in Africa and much so in South Africa in particular. The number of 
vitiligo patients in the UK is greater than half a million individuals. (14). In 2005, vitiligo 
was diagnosed in 25 (3.4%) of patients at a University Teaching Hospital in Nigeria. (15) The 
hospital-visiting rate prevalence of vitiligo in Korea during a three-year duration was 0.12% 
to 0.13%. (16) Vitiligo meanwhile contributed 18.9% of the etiologies of acquired 
hypochromic patches in Bamako, Mali. (17) Vitiligo is common in South Africa, and was 
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ranked by Hartshorne as the fourteenth most common dermatological disease in a study 
conducted in the five public academic hospitals in Johannesburg in 2003. (1) 
 
Causes and association with other diseases 
The causes of vitiligo are multifactorial including genetic and nongenetic factors. Twin and 
family studies have indicated the importance of genetic factors in the development of vitiligo. 
In these studies, a number of genes have been found to be vitiligo susceptible and most of 
them are also associated with other autoimmune diseases. Vitiligo can appear with or as a 
manifestation of several medical conditions. These diseases including Hashimoto thyroiditis, 
Graves’ disease, alopecia areata, myasthenia gravis, psoriasis, systemic lupus erythematosus, 
Sjogren’s syndrome, atopic dermatitis and Helicobacter pylori (HP) infection were found to 
be associated with vitiligo. (16, 18-21)  
 
Clinical Presentation 
Vitiligo presents with well-demarcated areas of pigment loss, usually symmetric. These 
vitiligo macules and patches are surrounded by normal skin and have discrete margins. The 
shape can vary from round, oval, irregular or linear. These lesions enlarge outwards over time 
as the disease progresses. This enlargement may be very slow almost to static or rapid 
depending on an individual. It is not known why this process is quick in some individuals and 
very slow in others. The course of the disease is unpredictable and vary between individual 
patients. Vitiligo lesions are less apparent in lightly pigmented individuals in contrast to 
darkly pigmented people where they are more visible. This is because of the contrast between 
vitiligo lesions and the surrounding normal dark skin. Vitiligo is usually asymptomatic but 
pruritus is sometimes reported by some patients.  Various classification systems for vitiligo 
have been suggested, leading to confusing terminology but generally it is classified as 
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localized, generalized and universal. Its localized when one area of the body or a unilateral 
segment is involved and is generalized when several parts of the body are affected. Universal 
vitiligo is where almost or the whole body is depigmented. 
 
Treatment  
Although there is no known definitive universal cure, available treatment options lead to 
satisfactory results in a good number of patients. Several treatment options are available and 
some are associated with side effects during their long-term use. Unfortunately, those with 
less or no side effects are limited or even not available at all in most health facilities. Some of 
the common treatment options are briefly discussed here. Corticosteroids can be used 
topically, intralesional or systemic but these are associated with side effects like skin atrophy. 
Topical calcineurin inhibitors including tacrolimus and pimecrolimus in form of ointment or 
cream can be used alone or in combination with topical steroids or phototherapy. These help 
to minimise the side effects of topical steroids. Unfortunately, topical calcineurin inhibitors 
are not available in resource limited hospital settings. Photo(chemo)therapy is also used; 
narrowband UVB has shown to be more effective than broadband UVB in the treatment of 
vitiligo. Short-term side effects include pruritus and xerosis. Surgical therapies are indicated 
for those patients who do not respond to medical treatment and are limited in most centres. 
Surgical options include minigrafting, grafting of cultured autologous melanocytes and 
others. Complete depigmentation is also a treatment option for those patients with widespread 
vitiligo who have only a few areas of normally pigmented skin in exposed parts of the body. 
Various therapeutic options can be combined to produce higher rates of success compared to 
monotherapy. Psychological support is of great importance in these patients.(11) Use of 
support groups and psychological counselling depending on the patient states is also helpful. 
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 Psychosocial burden of vitiligo 
 It is well known that vitiligo adversely affects the psychosocial aspects of vitiligo sufferers. 
It was reported in a study done at Khartoum Dermatologic Hospital in Sudan that suffering 
from vitiligo is responsible for psychological problems in a large number of vitiligo patients. 
(22) Vitiligo is cosmetically and psychologically devastating, and affects people of all races, 
skin types and various ethnic groups. (23) Due to the contrast between diseased and normal 
skin, patients with skin of colour are greatly affected both psychologically and socially. 
Therefore, the QoL may vary in different racial groups. (24) Vitiligo can significantly affect 
patients’ QoL, especially when it is on the exposed body parts or the genital area. (25) The 
QoL is altered in a significant number of individuals, despite the body surface area involved 
(generalised/localised vitiligo). Therefore, patients presenting with localised vitiligo may also 
have remarkable effects on QoL. (2) It was shown that the burden on QoL increases 
proportionally with extent of the disease, and may also involve sexual dysfunction and 
itching. Furthermore, various distributions of the disease match various forms of QoL 
impairments. (26) The Vitiligo Society of South Africa (VSSA) was established in May 2008 
due to the burden of vitiligo in South Africa. (27) 
 
The concept of quality of life in general and its assessment in Vitiligo 
‘Quality of life’ is a concept that was formulated from an arrangement of information about 
physical, social and psychological wellbeing of a person. This was promoted by the World 
Health Organisation as not only the absence of disease or infirmity, but as the ability of a 
person to be able to live a productive and enjoyable life. (28) QoL evaluation collects 
information from the patient about how he/she feels the effect of the diseases on his/her 
everyday life. This will be used to assess the benefits of treatment/management 
systematically and scientifically, as this is based on what is important to the patient.  (29) 
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Various QoL assessment tools can be used to demonstrate the details of the burden caused by 
vitiligo, and some of these questionnaires are the Dermatology Life Quality Index (DLQI), 
the Dermatology-specific quality of life, the Skin Index, and the vitiligo-specific Quality of 
Life Instrument. (23, 29-31) 
Studies evaluating the QoL amongst vitiligo patients have been published, however, the 
majority of these studies are from Europe. (3-5) Other studies on vitiligo and QoL were 
conducted amongst an Asian population. Su-ming Wong et al. in Malaysia, in their study, 
evaluated the QoL among Malaysian patients with vitiligo and found a moderate limitation 
on the QoL of their respondents. (6) Parsad et al. in India evaluated the DLQI score in their 
patients, and then how it affects the outcome of treatment. In this study, a mean DLQI score 
of 10.67 was reported, which is higher than that obtained in Malaysia of 6.40. This shows 
how vitiligo can affect patients differently in terms of their QoL, in different populations. It 
has been shown that vitiligo affects the quality of life of individuals from the same family, 
including those without disease, and sometimes may greatly affect considerable number of 
aspects of their daily living. (7, 32)  
In Africa, few studies on QoL and skin diseases in general and on vitiligo in particular have 
been undertaken. (9, 10, 33-35) Osman et al. in Sudan studied the psychological disturbances 
due to vitiligo in adult Sudanese vitiligo patients. Vitiligo was found to cause many more 
psychiatric disturbances than albinism in Nigeria among African adult subjects in a study 
done at a tertiary hospital. (22, 36) 
There are few studies evaluating the QoL among patients with vitiligo in Africa; Samson 
Kiprono et al. studied the QoL of vitiligo patients in Tanzania at the Regional Dermatology 
Training Center. (8) In South Africa, studies to evaluate the QoL of South Africans with 
other chronic skin diseases that affect their QoL have been carried out. (9, 10) Using PubMed 
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and Google scholar literature search, it would appear that no study on QoL and vitiligo has 
been conducted in South Africa.  
Therefore, our aim was to demonstrate how vitiligo has altered the QoL of our patients in 
South Africa. It was valuable opportunity to evaluate the influence of skin color on QoL 
impairment, since patients with different skin photo types were enrolled. 
 
 1.1 STUDY OBJECTIVES 
1) To evaluate the quality of life of vitiligo patients.   
2) To describe the demographic characteristics of vitiligo patients attending dermatology 
outpatient clinics.  
3) To test for associations between demographic characteristics and QoL. 
4) To determine treatment modalities (phototherapy, topical steroids and others). 
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CHAPTER 2 
2.0 MATERIALS AND METHODS 
 
Our study was a prospective cross-sectional study. We involved all patients meeting the 
inclusion criteria seen from October 2012 to January 2013 at CMJAH, CHBAH and HJH in 
Johannesburg. Patients attending the phototherapy daycare centre at CMJAH for 
phototherapy treatment of vitiligo and were meeting the criteria to be in the study were 
requested to be interviewed about their condition, and were added into our cohort. All 
patients who were meeting the inclusion criteria accepted the request to participate in the 
study. 
 
After obtaining ethics approval from the University of the Witwatersrand’s Ethics Committee 
on Human Research, and gaining permission from the CEOs of various health facilities, data 
was obtained from participants using the data collection sheet and DLQI questionnaire. This 
data was cross-checked and coded for subsequent statistical analysis. 
 2.1 STUDY DESIGN 
This is a prospective cross-sectional study assessing the QoL among all patients with vitiligo 
who consented to participate in this research. These patients were seen at the dermatology 
outpatients’ clinics at CMJAH, CHBAH and HJH as well as patients attending the 
phototherapy daycare centre at CMJAH. 
2.1.1 Study population 
The academic division of dermatology of The University of the Witwatersrand provides 
dermatological care to patients in the three public hospitals: CMJAH, CHBAH and HJH. 
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Patients with different skin phototypes attend these clinics. All patients aged 18 years and 
above who were diagnosed with vitiligo by a skin specialist, and were attending the 
dermatology outpatients’ clinics at CMJAH, CHBAH and HJH; as well as patients attending 
the phototherapy daycare centre at CMJAH, either as a new patient or as a follow-up case 
from October 2012 to January 2013, were recruited to participate in the study. 
2.1.2 Sampling 
Convenience sampling was employed. A total of 95 (ninety-five) patients that satisfied the 
criteria below to be included were asked to take part in our study. None of our patients 
objected the request 
Inclusion criteria: 
1. Outpatient diagnosed with vitiligo by a dermatologist clinically. 
2. Adult patient (Age≥18 years). 
3. Acceptance to take part in the study. 
Exclusion criteria: 
1. Inpatient. 
2. Less than 18 years of age. 
3. Patient who didn’t accept to take part in the study. 
 
 
 
 
9 
 
2.2 MEASUREMENTS 
The aim and nature of the study was explained by the investigator to all patients meeting the 
above inclusion criteria, and these patients were requested to take part in our study. Those 
who volunteered to participate were asked to sign a consent form. Information regarding 
demographic characteristics of the patient (example gender, age, and marital status etc.), 
clinical data on the localisation and the area of coverage of disease, treatment modality and 
the type of vitiligo after a clinical evaluation by a dermatologist was collected on a data 
collection sheet. The so-called ‘rule of 9s’ was used to measure the extent of the affected 
body surface.  
 
The English version of a widely validated questionnaire commonly used in quality of life 
studies, the Dermatology Life Quality Index, was administered. To overcome literacy and 
language differences; one of the nursing staff was asked to help with interpretation and 
translation to the respondents who were not fluent in English for both questionnaire and 
consent form. All recommendations for its clinical use were followed as outlined by the 
authors.  This questionnaire is user-friendly, and has been used in several other studies 
assessing QoL in other chronic skin diseases. (9,10) DLQI questionnaire is made up of ten 
questions with a maximum of four points each, the answers of each question range from ‘not 
at all’ to ‘very much’, which are scored from zero to three. If the patient answers ‘not 
relevant’, a score of zero is given. The total score is obtained by adding up the values of each 
question, which gives a total of 0 to 30, therefore 0 is the possible minimum total score, and 
30 is the possible maximum total score. The patient’s QoL is more greatly affected as the 
total score increases. Scores have the following meanings according to authors:  zero to one 
stands for no effect of the skin condition on the QoL of the patient, two to five are interpreted 
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as a small effect of the skin disorder on patient’s life, six to ten means that patient’s life is 
affected moderately by the skin disorder. Also, scores from eleven to twelve stands for a very 
large effect on the patient’s QoL by the skin condition; if the skin condition has extremely 
affected the life of a patient, then scores of twenty-one to thirty are given when evaluating the 
effect of a skin disease on the QoL of patients. An alternative way to express the DLQI is as a 
percentage of the added scores to thirty. We did not use the VitiQoL, because this instrument 
was developed recently, and is still in preliminary validation process. (30) 
 
2.3   DATA PROCESSING AND ANALYSIS 
2.3.1 Data entry  
Information from the questionnaire and the data collection sheets were captured into a 
Microsoft Excel spreadsheet for the reasons of cleaning and coding of the data. Cleaning was 
done by rechecking the data for possible missing values, extreme values, as well as verifying 
for internal consistency. For the purpose of data analysis, data coding was done, for example, 
the QoL scores of patients with vitiligo were summed up and categorised into their respective 
groups. 
2.3.2 Data analysis 
The cleaned and coded data in MS-Excel spreadsheet was transferred to statistical software 
(STATA version 12) for analysis. To assess patients’ demographic characteristics, we carried 
out descriptive analysis. Categorical variables such as race, gender and treatment modalities, 
frequencies and percentages were computed, whereas means and standard deviations were 
computed for numerical variables. To calculate the DLQI, we added up the score of each 
question, as well as the scores of all patients. The possible sum of the score ranges from a 
minimum of 0 to a maximum of 30. This information was presented in frequency tables and 
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bar graphs. For abnormally distributed data, medians and inter-quartile ranges were 
employed. Various statistical tests (Chi-square, ANOVA test) were used to test for 
associations between demographic characteristics (race and gender) and QoL. The significant 
test is set at p< 0.05. 
2.4 LIMITATIONS 
Patients were enrolled from tertiary health facilities, and therefore are mainly referred 
patients. These may be either those who didn’t respond to treatment at a lower level, or those 
who were greatly concerned about their skin condition, with a high total score not reflecting 
the true image of the effect of the disease on the QoL of patients in South Africa. Our study 
involved a limited sample, because these patients are referred to tertiary health facilities. 
There may therefore be a bias present. 
A majority of patients attending these public academic hospitals are black, due to their 
relative socio-economic status compared to that of other races. Due to higher colour contrast 
between normal and diseased skin in patients with skin of colour, and their large number 
compared to other races, there may be a bias when comparing the quality of life in this 
cohort. 
2.5 ETHICS 
The research proposal was submitted to the University of the Witwatersrand’s Ethics 
Committee on Human Research for assessment and approval before starting of this research. 
The clearance certificate number M121031 was obtained. Patient information was only used 
for this research, and details were kept confidential. In order to keep confidentiality of the 
respondent, coded names were used at every step for the entire study. The consent was 
obtained from CEOs of various health facilities, as well as from individual participants, 
before the start of data collection. One of the nursing staff was asked to help with 
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interpretation and translation of the content of the consent form and everything about the 
study for those patients who were not fluent in English.  
 
CHAPTER 3 
3.0 RESULTS 
3.1 DEMOGRAPHICS AND CLINICAL CHARACTERISTICS 
 
A total of ninety-five (n=95) patients took part in our study. Our cohort comprised sixty-two 
females (n=62, 65.26%), and thirty-three males (n=33, 34. 74%). A large number of our 
patients were between thirty-five and sixty years of age (n=52, 54.7%), followed by those 
who were above sixty years of age (n=24, 25.2%), and a small number less than thirty-five 
years of age (n=19, 20%). A majority of our patients identified as black (n=79, 83.16%), 
followed by those identified as coloured (n=12, 12.63%), where those identified as Indian 
and white (n=2, 2.11% each) were equal in number. Our patient’s age ranged between 18 to 
79 years, and the mean was 48.8 (SD=15.7) years. Ninety-four (n=94) of our patients were 
South Africans, and only one (n=1) patient was a Ugandan. A majority (n=43, 45.26%) of our 
patients were married, and only five (5.26%) were widowers. Thirty-seven patients were 
single (n=37, 38.95%). Ten (n=10, 10.53%) patients were divorced. The age at onset of the 
disease ranged from one year to seventy-seven years, with the mean age at onset of 39±17.9 
years. Table1 below shows detailed characteristics of our patients.  
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Table 1 Details of characteristics of all patients enrolled in the study 
Patients’ characteristics Total number of patients 
(n=95) 
Age (years), mean(range) 48.8(18-79)  
Gender, n (%) Male                                                     
33(34.7) 
 Female                                           
62(65.3) 
‘Race’, n (%) Black 79(83.2)  
White 2(2.1) 
Indian 2(2.1) 
Coloured 12(12.6) 
 
Nationality (%)                  
South African 94(98.95) 
Foreigner 1(1.05) 
                     
Marital status n (%)                  
Single  37(38.95)                  
Married 43(45.3)                  
Divorced 10(10.5)                  
Widower 5(5.3)                  
Occupation n (%) Pensioner 19(20)                  
Civil Servant 19(20)                  
Unemployed 16(16.8)                  
Business Person 9(9.5)                  
Other 32(33.7)                  
Family history of Vitiligo, n 
(%)                  
Yes 18(18.95)                  
No 77(81.1)                  
Age of onset (years), mean (range)  39.2 (1–77) 
Duration of disease (years), mean (range)  9.2 (0.1–46) 
Body surface area involved (%), mean (range) 19.2(1–95)  
Treatment modality, n (%)                   Topical corticosteroids 89(93.7)                  
Phototherapy 8(8.4)                  
Other 2(2.1)                  
Dermatology Life Quality Index, mean (range) 10.06 (0–28) 
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A family history of vitiligo was found in eighteen (n=18, 18.95%) patients. Generalised 
vitiligo was the commonest (n=60, 63.16%) type, and mucosal vitiligo was the least (n=2, 
2.11%). Exposed areas like the face (n=58, 61.05%), hands (n=49, 51.58%), legs (n=49, 
51.58%) and neck (n=40, 42.11%), were frequently affected. Genitals were involved in 
thirty-two (n=32, 33.68%) patients. Using the rule of nine, the involved body surface area 
was in the ranges of one (1%) to ninety-five percent (95%). Mean body surface area involved 
was nineteen (19.2%, SD=24.4) percent. Most (n=89, 93.86%) of our patients were on topical 
steroids as their treatment modality and only eight (n=8, 8.42%) patients were on 
phototherapy. Two (n=2, 2.13%) patients were attending a traditional healer.   
  
  
 
Figure 1 Localisation of Vitiligo 
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Figure 2 Types of Vitiligo 
 
 
3.2 QUALITY OF LIFE (QoL) 
The DLQI scores were ranging from 0 to 28 and the mean score was 10.06±6.5, which 
indicates moderate Quality of Life (QoL) impairment in our cohort. Symptoms and feelings 
of our patients were commonly affected, with twenty-seven patients feeling highly 
embarrassed of their skin condition (n=27, 28.42%), where nineteen (n=19, 20%) had an 
itchy skin, and or found their skin painful or stinging. 
 
 The mean DLQI scores in females was higher than it was in males, but that was not 
significant difference (P value=0.6). The mean DLQI scores increased with skin contrast, 
with those identified as white having the least (8), those identified as black and colored 
having the highest (10.06 and 10.58, respectively), with 9.5 for those identified as Indians. 
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The difference was not statistically significant between different DLQI scores of various 
races, using ANOVA test. 
 
 Individuals who were divorced had the highest mean DLQI score (11.2), widowers had the 
lowest (8), while the mean DLQI scores for unmarried and married individuals were 10.51 
and 9.65, respectively. Using the ANOVA test, there was no statistical difference between 
DLQI scores in different marital status. 
 
 The highest mean DLQI score was seen in unemployed individuals (13.4), where those doing 
business had the lowest (7.5). Pensioners, government employees and those doing other 
activities like traditional healers had mean DLQI scores in the same range (9.8, 9.7 and 9.3). 
Individuals aged less than 35 years and those between 35 and 60 years had a mean DLQI 
scores of 10.8 and 10.2, respectively, while the mean DLQI score of people aged above 60 
years was 9.0, so there was a decrease in mean DLQI score as age increases, but this was not 
statistically significant using ANOVA test (P value =0.67). 
 
 Patients who were undergoing phototherapy had a mean DLQI score of 13.8, compared to 
those who were not undergoing therapy, whose mean DLQI score was 9.7. The mean DLQI 
scores for patients on topical steroids and other treatment modalities were 10.07 and 8.5, 
respectively. Only seven (7) patients were on combination therapy, with a mean DLQI score 
of 15.8.  
 
Patients with generalised vitiligo had the highest mean DLQI score of 10.88, while those with 
segmental vitiligo had the lowest mean DLQI score of 7.14. Patients with mucosal vitiligo 
had mean DLQI score of 10, whereas for those with acrofacial and localised vitiligo were 
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10.22 and 6, respectively. No relationship between body surface area involved and DLQI 
scores seen (P value>0.05). DLQI scores did not statistically correlate with the duration of 
the disease.  
Table 2 below shows a comparison of mean DLQI scores and various patient characteristics 
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Table 2 Comparison of mean DLQI scores and various patient characteristics 
Patient variables Mean DLQI  p-value  
Gender Male 9.4                              
0.7                   
                                    
Female 10.4  
Race Black 10.06                   
>0.05 
 
White  8 
Indian 9.5 
Coloured 10.58 
                     
Marital status                 
Single  10.5                
>0.05                  
                  
Married 9.6 
Divorced 11.2 
Widower 8.0 
Occupation  Pensioner 9.88                
>0.05  
Civil servant 9.78 
Unemployed 13.38 
Business person 7.5 
Other 9.3 
Age groups  Less than 35 years 10.8                  
0.67  
35 years to 60 years 10.2 
Above 60 years 9.0 
Treatment 
modality                 
Currently on phototherapy 13.87                 
>0.05  
On treatment other than 
phototherapy  
9.71 
Type of Vitiligo  Segmental 7.1                   
>0.05  
Generalised 10.9 
Acrofacial 9.2 
Mucosal 10.0 
Localised 8.9 
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CHAPTER 4 
4.0 DISCUSSION AND CONCLUSIONS 
 4.1 DISCUSSION 
Mean dermatology life quality index score 
To our knowledge, our study is the first of its kind in South Africa looking at the QoL of 
patients suffering from vitiligo. The DLQI scores of our patients ranged from 0 to 28 and 
their mean was 10.06 ±6.52 which indicates moderate Quality of life (QoL) impairment. This 
is slightly lower than the mean DLQI score ±SD of 10.67 ±4.56 reported by Parsad et al. in 
India, but much lower than 14.72 found by Al Robae et al. in Saudi Arabia. (7, 37) In our 
study the mean DLQI score (10.06±6.52) is slightly higher than that found by Belhadjali et al. 
of 9.4 ± 4 in France; much higher than that found by Wong et al. of 6.40 in Malaysia; by 
Kiprono et al. of 7.20 in Tanzania; by Dolatshahi et al. of 8.16 in Iran; by Kostopoulou et al. 
of 7.17 in France; and by Radtke et al. of 7 in Germany. (6, 8, 38-41) It is important to note 
that except for  the results from the Tanzanian study, most of other studies were from mainly 
lightly skinned patients compared to our patients where the majority were black patients. 
 
Demographic characteristics and quality of life  
In our study, as in previous studies, females constituted the majority of participants (n=62, 
65.26%), almost two times the number of males (n=33, 34. 74%). It has been reported that 
women have a greater feeling of embarrassment and are more concerned about the disease, 
seeking out medical care more often than men. (5, 17, 34)  In our study, gender or marital 
status did not statistically relate to DLQI scores, which was also demonstrated in the studies 
done in Malaysia and France. In contrast, in one study done in Belgium, sex was signiﬁcantly 
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associated with the DLQI Score, and in general, women had higher scores and a mean of 
6.45, whereas men had a mean of 3.13. (5, 6, 40) Significant variation of DLQI scores 
between males and females was also reported in Iran, France and Germany, in contrast to 
studies done by Kent et al. and Parsad et al.  (7, 38, 41-43) 
A decrease in a mean DLQI score, with an increasing age, was observed, though this was not 
statistically significant. (P-value=0.67) Individuals aged less than 35 years and those between 
the age of 35 and 60 years had mean DLQI scores of 10.8 and 10.2, respectively, while it was 
9.0 for patients aged above 60 years. Young people are more likely to be concerned about the 
appearance of their skin. The same findings were reported by Radtke and his colleagues (41) 
Quality of life and disease characteristics 
The symptoms and feelings of our patients were commonly affected, with twenty-seven 
(n=27, 28.42%) patients feeling great embarrassment or concern about the appearance of their 
skin, where nineteen (n=19, 20%) had an itchy and/or painful or stinging skin. This is the 
same as findings by Wong and Bab, where several of their patients were embarrassed because 
of their skin disease, and others had itchy skin at vitiliginous areas. (6) In this study, 62.5% of 
patients with itchy skin were on phototherapy treatment during the time when the study was 
conducted. In one study, 20% of patients had pruritus, which was associated with vitiligo and 
which could not be attributed to other comorbidities like diabetes or thyroid disease. (44) 
Pruritus thus seems to be a common finding in vitiligo patients. Ongenae et al. reported the 
same findings as those of our cohort for Question 2, but differed for Question 1, where their 
patients with vitiligo had a very low score for Question 1 (symptoms), however, some 
patients reported itchy or burning skin when exposed to the sun. (5) 
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A family history of vitiligo was mentioned in eighteen (n=18, 18.95%) patients. This is 
higher than 11⁄48 (23%) reported by Kostopoulou et al. in France. (40) More studies are 
needed to assess whether or not a family history of vitiligo is common among African rather 
than Caucasian patients, as a majority of our patients were identified as black. Family history 
of vitiligo or duration of the disease were not significantly associated with DLQI scores in 
our study. This is the same as findings reported by Ongenae et al. in Belgium. Our findings 
are partly contested by finding of Radtke et al., where increasing duration of the disease led 
to a higher impairment in QoL. Radtke et al. did not test the relationship between the DLQI 
score and family history of vitiligo. (5, 41) 
Although it was not of significance statistically, the mean DLQI scores increased with the 
skin contrast, with those identified as white having the least (8), those identified as black and 
colored having the highest (10.06 and 10.58, respectively), and those identified as Indian with 
9.5. The low number of white and Indian patients may be the explanation for the absence of a 
statistically significant difference when comparing the DLQI scores in different races. Studies 
have suggested that the more the skin contrast between pigmented and depigmented skin, the 
greater the QoL impairment.(39) 
 
Exposed areas like the face (n=58, 61.05%), hands (n=49, 51.58%), legs (n=49, 51.58%) and 
neck (n=40, 42.11%), were frequently affected. In line with various other studies, visibility of 
the lesion did not significantly correlate with DLQI scores in our study. This contrasts with 
the findings of Wong and Baba in Malaysia. However, it has been reported several times that 
cosmetic camouflage can help in improving QoL in chronic skin diseases. (6, 36, 42, 45, 46) 
We did not find a significant relationship when comparing increasing body surface area with 
vitiligo lesions and DLQI scores (p >0.05). However, several authors reported varying results 
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when investigating effect of the size of body surface affected on QoL of their respondents.  
(5, 7, 38, 41, 43) 
As previously reported by Wong and Bab in Malaysia, duration of disease did not statistically 
correlate with DLQI scores in our study. This contrasts findings reported in India, as well as 
the findings of the study by Radtke et al. in Germany, where a much higher limitation in their 
patients’ QoL was observed. (6, 7, 41) 
Patients who were on phototherapy treatment did not show improved DLQI scores compared 
to those who were not on phototherapy. This differs from the findings of Wong et al., where a 
significant relationship was observed between DLQI scores and phototherapy. This may be 
explained by the possibility of poor response to phototherapy treatment in our cohort that 
may have a negative psychological influence on our patients. (6) Studies have shown that a 
good response to medical treatment of vitiligo as well as psychological therapy improves 
DLQI scores. (7, 47) 
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4.2 CONCLUSION 
This was a cross-sectional prospective study done at tertiary public hospitals, therefore may 
not show the real impact of vitiligo on the QoL of all South Africans with the condition. Most 
of our patients were referred, probably the most affected and difficult to treat at lower heath 
facilities, with a high average Dermatology Life Quality Index score.  
Our study has demonstrated that vitiligo moderately affects the QoL of adult South Africans. 
In diseases like vitiligo, which are very difﬁcult to treat, with limited treatment options and 
adversely affecting QoL of patients, this would provide an argument for psychological 
management suggestions, such as the establishment of psychodermatology clinics at our 
referral hospitals. This would help patients’ management both psychologically and 
physically. It was well-demonstrated by Parsad D et al. that there is a low response to a given 
treatment option in patients with higher DLQI scores, therefore, addressing psychosocial 
issues may improve treatment outcomes. (7) 
This will equip our training dermatologists (registrars) with the knowledge to manage most 
skin disorders affecting the QoL of patients more effectively. Moreover, training of 
dermatologists in other treatment options like skin grafting and needling as well as availing 
these options to dermatologists would be of similar value. It has been shown by Bin Saif et al. 
that vitiligo not only affects the QoL of the patient in particular, but also affects the QoL of 
the entire family. (32) 
Though vitiligo is an asymptomatic disease, our study has alongside other studies well 
demonstrated that vitiligo affects the QoL of patients, and that therefore, psychological 
factors ought to be taken into more serious consideration when managing these patients.  
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APPENDICES 
APPENDIX A.  Dermatology Life Quality Index Questionnaire             
©AY Finlay. GK Khan. April 1992  
1 Over the last week, how itchy, sore, 
painful or stinging has your skin been?                
  
Very much 
A lot           
A little  
 Not at all  
 
  
2  Over the last week, how embarrassed or 
self-conscious have you been because of 
your skin?     
Very much 
A lot         
 A little    
Not at all 
  
 
3 Over the last week ,how much has your 
 skin interfered  with your going 
Shopping or looking after your home or 
garden?  
Very much 
A lot        
 A little    
Not at all 
 Not relevant 
 
4 Over the last week, how much has your 
skin influenced the clothes you wear? 
Very much 
A lot        
 A little   
 Not at all 
 Not relevant 
 
5 Over the last week, how much has your 
skin affected any social or leisure 
activities? 
 Very much 
  A lot       
  A little   
  Not at all 
 Not relevant 
 
6 Over the last week, how much has your 
skin made it difficult for you to do any 
sport? 
Very much 
A lot          
 A little    
Not at all 
 Not relevant 
 
7 Over the last week, has your skin prevented 
you from working or studying? 
Yes 
No 
If  “No”, over the last week, how much has  
your skin been a problem at 
Work or studying? 
Yes 
No 
 
 
A lot       
 
A little    
 
Not at all 
 
 Not relevant 
 
8 Over the last week, how much has your 
skin created problems with your 
partner or any of your close friends 
or relatives? 
Very much 
A lot       
 A little   
 Not at all 
 Not relevant 
 
9 Over the last week, how much has your 
skin caused any sexual difficulties? 
Very much 
A lot           
A little   
 Not at all 
 Not relevant 
 
10 Over the last week ,how much of a  
problem has the treatment for your  
skin been, for example by making 
your home messy, or by taking up time? 
Very much 
A lot       
 A little    
Not at all 
 Not relevant 
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APPENDIX B.    Data collection sheet 
1. Unique patient ID:                                                                                2.Date     
Demographic data 
3.  Age: 
4. Gender:                   Male                      Female 
5. Race:          White           Black                 Coloured                      Indian  Others 
6. Nationality: 
7. Marital status:           Single           Married              Divorced 
8. Occupation: 
Clinical characteristics 
9. Age at onset: 
10. Duration of the disease: 
11. Family history of vitiligo:          Yes                                     No 
12. Localisation of disease: 
                   Legs                               Neck                              Face                                    Hands 
13.                  Feet                                Trunk                                Genitals                       Breast      
14. Body surface area involved: 
 15. Treatment modalities:                Phototherapy  
                                                         Topical steroids  
                                                        Others 
16. Type of vitiligo:             Localised 
                Segmental                Generalised         Acrofacial 
                Mucosa                   Universal 
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APPENDIX C. Patient’s Informed Consent  
QUALITY OF LIFE AMONG VITILIGO PATIENTS ATTENDING 
DERMATOLOGY OUTPATIENT CLINICS IN JOHANNESBURG  
Greetings and introduction: Good morning/good afternoon. 
My name is Dr. Elisah Agaba. I am specialising in skin diseases at the University of 
Witwatersrand. I am interested in finding out how much this condition (vitiligo) has affected 
your life. This will be achieved by doing a research study. Research is a process of 
discovering the answer to a question. 
Invitation to take part in the study: I hereby invite you to take part in the study entitled 
‘Quality of life among vitiligo patients attending Dermatology outpatient clinics in 
Johannesburg’.   
What is involved in the study: We are interested in finding out how much this condition 
(vitiligo) has affected the activities of daily living of our patients, including yourself. If you 
accept to participate, you will answer 10 questions for us. This will take you less than fifteen 
minutes. I will get some general information from your hospital file, such as age, marital 
status, etc. and information related to your treatment, then examine you. All our patients 
attending our dermatology outpatient clinics either for the first time or as follow-up with the 
same condition during the study period will be requested to participate in the study. 
Voluntary participation:  It is your choice whether or not to accept or refuse to participate 
or pull-out from this research anytime, or as the need arises. You will not be penalised or lose 
benefits because you have refused or withdrawn from this research. You will continue 
receiving treatment as you should. 
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Has the research received ethics approval: Permission to undertake this research has been 
received from the University of Witwatersrand Ethics Committee and the CEO of Charlotte 
Maxeke Johannesburg Academic Hospital/Chris Hani Baragwanath Academic Hospital/ 
Helen Joseph Hospital. 
Confidentiality: All efforts will be taken to keep your private information as confidential 
as possible. Collected information will be managed anonymously, and given research 
numbers and will not bear your names. Only the investigators will have access to the data. 
Contact details: For further information, queries and reporting of study related events, 
Professor Deepak Modi can be contacted any time on the following numbers: 
Mobile: 0834577090, Office: 0114883644 
Alternatively: Dr. Elisah Agaba  
Mobile: 0717873679 
Informed consent to be signed by the patient 
I, the undersigned. Mr./Ms./Mrs.……………… 
Hereby testify that the procedure and the reason for this research was well explained to me 
by Dr……………I furthermore confirm my understanding that my taking part in this 
research is totally of my own will and that I can easily withdraw consent at any time. 
Patient’s Surname………………………………………Signature                                                      
Date:  
Investigator’s Name…………………………………Signature                                                      
Date: 
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